Holding: In IBSA Institut Biochimique, S.A.
v. Teva Pharms. USA, Inc., --F.3d__ (Fed. Cir. July 31, 2020),
the U.S. Court of Appeals for the Federal Circuit (Judges PROST,
Reyna, and Hughes) affirmed the district court's decision that
certain IBSA's claims were invalid as indefinite.
Background: IBSA's U.S. Pat. 7,723,390,
claim 1, reads: A pharmaceutical composition comprising thyroid
hormones or their sodium salts in the form of either:
- a) a soft elastic capsule consisting
of a shell of gelatin material containing a liquid or
half-liquid inner phase ..., said liquid
or half-liquid inner phase being in direct
contact with said shell without any interposed layers, or
- b) a swallowable uniform soft-gel
matrix .... (emphasis added.)